Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Trial Identifier: D361FC00001
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT05008055
Start Date: November 2021
Primary Completion Date: December 2024
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, BC Victoria, BC, CA, V8R 6V5
CA, ON Toronto, ON, CA, M5G 2M9
DK Aarhus N, DK, DK8200
DK Roskilde, DK, 4000
ES Badalona, ES, 08003
ES Barcelona, ES, 08035
ES Madrid, ES, 28040
ES Madrid, ES, 28046
ES Salamanca, ES, 37007
FR La Tronche, FR, 38700
FR Lille Cedex, FR, 59037
FR POITIERS, FR, 86021
FR villejuif, FR, 94805
GB Cambridge, GB, CB2 0QQ
GB Glasgow, GB, G12 0YN
GB Hampshire, GB, SO16 6YD
GB London, GB, EC1A 7BE
GB Manchester, GB, M20 4BX
GB Oxford, GB, OX4 6LB
GB Plymouth, GB, PL6 8DH
GB Sutton, GB, SM2 5PT
KR Busan, KR, 49241
KR Seoul, KR, 3722
KR Seoul, KR, 5505
KR Seoul, KR, 06351
KR Seoul, KR, 3080
US, CA Duarte, CA, US, 91010
US, CA Los Angeles, CA, US, 90095
US, GA Atlanta, GA, US, 30322
US, TX Dallas, TX, US, 75246
US, TX Houston, TX, US, 77030